These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 34875656)

  • 1. PD-1 Blockade Elicits Ongoing Remission in Two Cases of Refractory Microsatellite-Stable Cancer Harboring a POLE Mutation.
    Schenck K; Masetti M; Pfarr N; Lorenzen S
    Oncol Res Treat; 2022; 45(4):222-226. PubMed ID: 34875656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a
    Gong J; Wang C; Lee PP; Chu P; Fakih M
    J Natl Compr Canc Netw; 2017 Feb; 15(2):142-147. PubMed ID: 28188185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA Polymerase ɛ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity.
    Castellucci E; He T; Goldstein DY; Halmos B; Chuy J
    Oncologist; 2017 May; 22(5):497-502. PubMed ID: 28465371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon.
    Rousseau B; Bieche I; Pasmant E; Hamzaoui N; Leulliot N; Michon L; de Reynies A; Attignon V; Foote MB; Masliah-Planchon J; Svrcek M; Cohen R; Simmet V; Augereau P; Malka D; Hollebecque A; Pouessel D; Gomez-Roca C; Guimbaud R; Bruyas A; Guillet M; Grob JJ; Duluc M; Cousin S; de la Fouchardiere C; Flechon A; Rolland F; Hiret S; Saada-Bouzid E; Bouche O; Andre T; Pannier D; El Hajbi F; Oudard S; Tournigand C; Soria JC; Champiat S; Gerber DG; Stephens D; Lamendola-Essel MF; Maron SB; Diplas BH; Argiles G; Krishnan AR; Tabone-Eglinger S; Ferrari A; Segal NH; Cercek A; Hoog-Labouret N; Legrand F; Simon C; Lamrani-Ghaouti A; Diaz LA; Saintigny P; Chevret S; Marabelle A
    Cancer Discov; 2022 Jun; 12(6):1435-1448. PubMed ID: 35398880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. POLE somatic mutations in advanced colorectal cancer.
    Guerra J; Pinto C; Pinto D; Pinheiro M; Silva R; Peixoto A; Rocha P; Veiga I; Santos C; Santos R; Cabreira V; Lopes P; Henrique R; Teixeira MR
    Cancer Med; 2017 Dec; 6(12):2966-2971. PubMed ID: 29072370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-Infiltrating Lymphocytes, Tumor Mutational Burden, and Genetic Alterations in Microsatellite Unstable, Microsatellite Stable, or Mutant
    Keshinro A; Vanderbilt C; Kim JK; Firat C; Chen CT; Yaeger R; Ganesh K; Segal NH; Gonen M; Shia J; Stadler Z; Weiser MR
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy.
    Ahn SM; Ansari AA; Kim J; Kim D; Chun SM; Kim J; Kim TW; Park I; Yu CS; Jang SJ
    Oncotarget; 2016 Oct; 7(42):68638-68649. PubMed ID: 27612425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring
    Wen L; Chen Z; Ji X; Fong WP; Shao Q; Ren C; Cai Y; Li B; Yuan Y; Wang D; Li Y
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.
    Mehnert JM; Panda A; Zhong H; Hirshfield K; Damare S; Lane K; Sokol L; Stein MN; Rodriguez-Rodriquez L; Kaufman HL; Ali S; Ross JS; Pavlick DC; Bhanot G; White EP; DiPaola RS; Lovell A; Cheng J; Ganesan S
    J Clin Invest; 2016 Jun; 126(6):2334-40. PubMed ID: 27159395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed Cell Death Protein 1 Blockade Elicits Ongoing Remission in 2 Cases of Refractory Epstein-Barr Virus-Associated Metastatic Gastric Carcinoma.
    Masetti M; Lindinger M; Lorenzen S
    Oncol Res Treat; 2022; 45(6):375-379. PubMed ID: 35220300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and Molecular Characterization of
    Garmezy B; Gheeya J; Lin HY; Huang Y; Kim T; Jiang X; Thein KZ; Pilié PG; Zeineddine F; Wang W; Shaw KR; Rodon J; Shen JP; Yuan Y; Meric-Bernstam F; Chen K; Yap TA
    JCO Precis Oncol; 2022 Feb; 6():e2100267. PubMed ID: 35108036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. POLE/POLD1 mutation and tumor immunotherapy.
    Ma X; Dong L; Liu X; Ou K; Yang L
    J Exp Clin Cancer Res; 2022 Jul; 41(1):216. PubMed ID: 35780178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency.
    Bourdais R; Rousseau B; Pujals A; Boussion H; Joly C; Guillemin A; Baumgaertner I; Neuzillet C; Tournigand C
    Crit Rev Oncol Hematol; 2017 May; 113():242-248. PubMed ID: 28427513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of immune checkpoint inhibitors for patients with advanced stage microsatellite stable colorectal cancer and high tumor mutation burden: quantity or quality?
    Vegivinti CTR; Gonzales Gomez C; Syed M; Ferrell M; Cheng S; Singhi A; Saeed A; Sahin IH
    Expert Opin Biol Ther; 2023; 23(7):595-601. PubMed ID: 37318031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer.
    Song Z; Cheng G; Xu C; Wang W; Shao Y; Zhang Y
    Lung Cancer; 2018 Apr; 118():57-61. PubMed ID: 29572003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymerase epsilon mutations and concomitant β2-microglobulin mutations in cancer.
    Voutsadakis IA
    Gene; 2018 Mar; 647():31-38. PubMed ID: 29320758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
    Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL
    Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.
    Howitt BE; Shukla SA; Sholl LM; Ritterhouse LL; Watkins JC; Rodig S; Stover E; Strickland KC; D'Andrea AD; Wu CJ; Matulonis UA; Konstantinopoulos PA
    JAMA Oncol; 2015 Dec; 1(9):1319-23. PubMed ID: 26181000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease.
    Momen S; Fassihi H; Davies HR; Nikolaou C; Degasperi A; Stefanato CM; Dias JML; Dasgupta D; Craythorne E; Sarkany R; Papa S; Nik-Zainal S
    Cold Spring Harb Mol Case Stud; 2019 Oct; 5(5):. PubMed ID: 31645345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab and Trastuzumab in High Tumor Mutational Burden and POLE-Mutated HER2-Positive Refractory Breast Cancer.
    Zhang L; Chen Y; Lv Y; Jiao S; Zhao W
    Oncologist; 2022 Apr; 27(4):245-250. PubMed ID: 35380719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.